The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate

British Journal of Clinical Pharmacology

Volumn 63, Issue 2, 2007, Pages 224-231

  Atthobari, Jarir ^a   Gansevoort, Ron T ^a   Visser, Sipke T ^a   De Jong, Paul E ^b   De Jong Van Den Berg, Lolkje T W ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Blood pressure; Glomerular filtration rate; Hormonal contraceptives; Urinary albumin excretion

Indexed keywords

CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; COHORT ANALYSIS; DATA ANALYSIS; DISEASE EXACERBATION; DRUG EFFECT; DRUG WITHDRAWAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HORMONAL CONTRACEPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

ADULT; AGED; ALBUMINS; ALBUMINURIA; BLOOD PRESSURE; COHORT STUDIES; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RISK FACTORS;

EID: 33846062156     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02747.x     Document Type: Article

References (29)

1. Weir RJ. When the pill causes a rise in blood pressure. Drugs 1978; 16: 522-7.
2. Schunkert H, Danser AH, Hense HW, Derkx FH, Kurzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997; 95: 39-45.
3. Ahmed SB, Hovind P, Parving HH, Rossing P, Price DA, Laffel LM, Lansang MC, Stevanovic R, Fisher ND, Hollenberg NK. Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 2005; 28: 1988-94.
4. Kang AK, Duncan JA, Cattran DC, Floras JS, Lai V, Scholey JW, Miller JA. Effect of oral contraceptives on the renin angiotensin system and renal function. Am J Physiol Regul Integr Comp Physiol 2001; 280: R807-13.
5. Ribstein J, du Halimi JMCG, Mimran A. Renal characteristics and effect of angiotensin suppression in oral contraceptive users. Hypertension 1999; 33: 90-5.
6. Curtis KM, Chrisman CE, Peterson HB, WHO Programme for Mapping Best Practices in Reproductice Health. Contraception for women in selected circumstances. Obstet Gynecol 2002; 99: 1100-12.
7. Lubianca JN, Faccin CS, Fuchs FD. Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception 2003; 67: 19-24.
8. Lubianca JN, Moreira LB, Gus M, Fuchs FD. Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension. J Hum Hypertens 2005; 19: 451-5.
9. Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G, Colditz GA, Stampfer MJ. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94: 483-9.
10. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LTW. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 2001; 161: 2000-5.
11. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-26.
12. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in non-insulin-dependent diabetics. Diabet Med 1984; 1: 17-19.
13. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300: 297-300.
14. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413-8.
15. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J Hum Hypertens 1997; 11: 727-32.
16. Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans ROB, Janssen WMT, Grobbee DE, de Jong PE. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in the general population. Circulation 2002; 106: 1777-82.
17. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988; 2: 530-3.
18. Woods JW. Oral contraceptives and hypertension. Hypertension 1988; 11: II11-II15.
19. Hollenberg NK, Williams GH, Burger B, Chenitz W, Hoosmand I, Adams DF. Renal blood flow and its response to angiotensin II. An interaction between oral contraceptive agents, sodium intake, and the renin - angiotensin system in healthy young women. Circ Res 1976; 38: 35-40.
20. Pinto-Sietsma SJ, Janssen WM, Hillege HL, De Navis GZD, de Jong PE. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 2000; 11: 1882-8.
21. Verhave JC, Gansevoort RT, Hillge HL, de Zeeuw D, Curhan GC, de Jong PE. Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function. J Am Soc Nephrol 2004; 15: 1316-22.
22. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT. Pharmacy data in epidemiological studies: an easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf 2002; 11: 379-84.
23. WHO Collaborating Centre for Drugs Statistics Methodology. ATC/ DDD Index 2005. Available at http://www.whocc.no/atcddd Last accessed 16 February 2005.
24. Health Care Insurance Board. Dutch Pharmacotherapeutic Guidelines. Amstelveen: Health Care Insurance Board 2003.
25. Gordon MS, Chin WW, Shupnik MA. Regulation of angiotensinogen gene expression by estrogen. J Hypertens 1992; 10: 361-6.
26. Doring A, Frohlich M, Lowel H, Koenig W. Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 2004; 172: 281-6.
27. Van Rooijen M, Hansson LO, Frostegard J, Silveira A, Hamstein A, Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 2006; 4: 77-82.
28. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low dose oral contraceptives and cardiovascular arterial disease: a meta analysis. J Clin Endocrinol Metab 2005; 90: 3863-70.
29. Van Den Bosch MA, Kemmeren JM, Tanis BC, Mali WP, Helmerhorst FM, Rosendaal FR, Algra A, Van Der Graaf Y. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost 2003; 1: 439-44.